What's Happening?
Space agencies, including the European Space Agency, are addressing the issue of astronauts losing their eyesight during prolonged space missions. This condition, known as Spaceflight-associated neuro-ocular syndrome (SANS), affects about 70% of astronauts on the International
Space Station. The condition is caused by bodily fluids accumulating in the head due to low gravity, leading to changes in the eye and brain. To combat this, the ESA has partnered with British startup Siloton to develop a compact eye-scanning device that can be used in space without real-time ground support.
Why It's Important?
The development of this technology is crucial as space agencies prepare for longer missions, such as those planned for the Artemis program to the moon and beyond. Vision impairment poses a significant risk to astronauts' operational capabilities and long-term health. By addressing this issue, space agencies aim to ensure the safety and effectiveness of future deep space missions. The technology also represents a significant advancement in medical monitoring in space, potentially leading to broader applications in remote healthcare.
What's Next?
As the technology is further developed, it will likely undergo testing on the International Space Station to assess its effectiveness in monitoring and preventing ocular degeneration. The data collected could lead to new treatments or preventive measures for SANS. Additionally, the success of this technology could pave the way for its use in other remote or extreme environments on Earth, enhancing medical care in isolated areas.
